

Appendix 5—Measures of association between First Nation status (reference general population) and each of the study outcomes, matched cohort#3 (Benchimol and colleagues case definition)

Outcomes	Stratified analysis					
	Full-group analysis (n=708)		Crohn's Disease (n=365)		Ulcerative Colitis (n=343)	
	Unadjusted HR (95%CI)	Adjusted HR (95%CI)*	Unadjusted HR (95%CI)	Adjusted HR (95%CI)**	Unadjusted HR (95%CI)	Adjusted HR (95%CI)** *
Outpatient gastroenterologist visit	1.11 (0.90-1.38)	1.17 (0.93-1.45)	0.85 (0.59-1.24)	0.92 (0.63-1.35)	1.34 (1.02-1.77)	1.36 (1.03-1.80)
Colonoscopy	1.19 (0.97-1.47)	1.11 (0.90-1.38)	1.04 (0.72-1.50)	1.07 (0.73-1.55)	1.13 (0.87-1.47)	1.15 (0.88-1.49)
Prescription claim for IBD	0.59 (0.47-0.74)	0.50 (0.40-0.63)	0.56 (0.38-0.82)	0.54 (0.36-0.80)	0.48 (0.36-0.64)	0.49 (0.37-0.65)
Prescription claim of a Biologic	0.68 (0.41-1.13)	0.78 (0.47-1.30)	0.78 (0.40-1.55)	0.78 (0.39-1.56)	0.72 (0.34-1.53)	0.77 (0.36-1.64)
Prescription claim of an IM	0.73 (0.50-1.06)	0.83 (0.56-1.21)	0.72 (0.43-1.23)	0.70 (0.41-1.20)	0.93 (0.54-1.59)	0.98 (0.57-1.70)
Prescription claim of a 5-ASA	0.69 (0.55-0.87)	0.54 (0.43-0.69)	0.64 (0.41-0.98)	0.61 (0.40-0.95)	0.51 (0.39-0.68)	0.51 (0.39-0.68)
IBD-specific hospitalization	1.26 (0.95-1.67)	1.30 (0.98-1.74)	1.53 (1.02-2.28)	1.37 (0.91-2.08)	1.23 (0.83-1.83)	1.22 (0.82-1.82)
IBD-related hospitalization	1.46 (1.13-1.89)	1.50 (1.16-1.96)	1.67 (1.14-2.45)	1.51 (1.02-2.24)	1.48 (1.04-2.10)	1.48 (1.04-2.10)
Surgery for IBD	1.15 (0.81-1.63)	1.14 (0.80-1.63)	1.16 (0.66-2.02)	1.10 (0.63-1.95)	1.16 (0.74-1.84)	1.17 (0.74-1.86)

HR: hazard ratio, 95%CI: 95% confidence interval. Bold values denote statistically significant results.

* Models adjusted by rural or urban status, and diagnostic type (n=707).

** Crohn's Disease group, models adjusted by rural or urban status (n=364).

*** Ulcerative colitis group, models adjusted by rural or urban status.

Appendix 5, as supplied by the authors. Appendix to: Marques Santos JD, Fowler S, Jennings D, et al. Health care utilization differences between First Nations people and the general population with inflammatory bowel disease: a retrospective cohort study from Saskatchewan, Canada. CMAJ Open 2022. doi:10.9778/cmajo.20220118. Copyright © 2022 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.